Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest

Immuneering Corporation (NASDAQ:IMRX) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1% from the December 15th total of 7,635,854 shares. Approximately 21.9% of the shares of the company are short sold. Based on an average daily volume of 1,780,211 shares, the short-interest ratio is currently 6.1 days. Based on an average daily volume of 1,780,211 shares, the short-interest ratio is currently 6.1 days. Approximately 21.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Immuneering in a research report on Tuesday, September 30th. Leerink Partnrs raised Immuneering to a “strong-buy” rating in a report on Friday, October 31st. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research report on Thursday, November 13th. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Trading Down 1.3%

IMRX stock traded down $0.06 during trading on Friday, hitting $4.58. 1,571,991 shares of the stock traded hands, compared to its average volume of 3,135,325. The stock has a market cap of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48. Immuneering has a one year low of $1.10 and a one year high of $10.08. The company has a 50 day simple moving average of $6.37 and a 200 day simple moving average of $5.78.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, analysts predict that Immuneering will post -1.86 earnings per share for the current fiscal year.

Insider Transactions at Immuneering

In related news, Director Peter Feinberg acquired 20,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were bought at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the acquisition, the director owned 135,441 shares in the company, valued at $589,168.35. This trade represents a 17.32% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have acquired 24,924 shares of company stock valued at $108,400. Company insiders own 22.90% of the company’s stock.

Institutional Trading of Immuneering

Large investors have recently made changes to their positions in the business. Sanofi acquired a new position in shares of Immuneering during the third quarter valued at $18,960,000. Vanguard Group Inc. raised its holdings in Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after purchasing an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC acquired a new position in Immuneering during the 3rd quarter valued at about $6,602,000. Blue Owl Capital Holdings LP bought a new position in shares of Immuneering in the 3rd quarter valued at about $3,850,000. Finally, Monashee Investment Management LLC acquired a new stake in shares of Immuneering during the 3rd quarter worth approximately $2,100,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.